IKNA
NASDAQIkena Oncology Inc.
Price$1.42-0.04 (-2.41%)
2025-06-092025-07-25
Latest news
25 items- SECIkena Oncology Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - ImageneBio, Inc. (0001835579) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Yarema Kristin4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERDirector Orbimed Advisors Llc was granted 83,611 shares (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
- INSIDERDirector Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERDirector Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERChief Financial Officer Marango Jotin was granted 15,776 shares and covered exercise/tax liability with 4,630 shares (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERPrincipal Accounting Officer Butler Erin was granted 3,051 shares (SEC Form 4)4 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 3 filed by new insider Butler Erin3 - ImageneBio, Inc. (0001835579) (Issuer)
- INSIDERSEC Form 3 filed by new insider Yarema Kristin3 - ImageneBio, Inc. (0001835579) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
- SECIkena Oncology Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Leadership Update, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure8-K - ImageneBio, Inc. (0001835579) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.SCHEDULE 13D/A - ImageneBio, Inc. (0001835579) (Subject)
- SECIkena Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Ikena Oncology, Inc. (0001835579) (Filer)
- PRInmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 MillionThe combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025 ImageneBio, Inc. will continue to drive the ongoing Phase 2b clinical trial of non-depleting anti-OX40 monoclonal antibody, IMG-007, in patients with moderate-to-severe atopic dermatitis Phase 2b topline readout for IMG-007 in atopic dermatitis expected in the fourth quarter of 2026 SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company dedicated to developing disease-modifying treatments for immunological/autoimmune and inflamma
- SECSEC Form 10-Q filed by Ikena Oncology Inc.10-Q - Ikena Oncology, Inc. (0001835579) (Filer)
- SECSEC Form 8-K filed by Ikena Oncology Inc.8-K - Ikena Oncology, Inc. (0001835579) (Filer)
- PRIkena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged CompanyBOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") and Inmagene Biopharmaceuticals ("Inmagene") today announced the appointment of Kristin Yarema, Ph.D. as Chief Executive Officer of ImageneBio ("Imagene"), of the combined company after the anticipated closing. "We are thrilled to welcome Dr. Yarema to the team. Kristin is bringing expertise to the team that will push the company, and our lead program, IMG-007, towards significant milestones," commented David Bonita, an Ikena director and a continuing board member of the combined company. "Her experience as a public company CEO and commercial leadership are valuable additions to this team.
- SECSEC Form 8-K filed by Ikena Oncology Inc.8-K - Ikena Oncology, Inc. (0001835579) (Filer)
- SECSEC Form D filed by Ikena Oncology Inc.D - Ikena Oncology, Inc. (0001835579) (Filer)
- SECSEC Form 8-K filed by Ikena Oncology Inc.8-K - Ikena Oncology, Inc. (0001835579) (Filer)
- SECSEC Form 8-K filed by Ikena Oncology Inc.8-K - Ikena Oncology, Inc. (0001835579) (Filer)
- PRIkena Oncology Announces Stockholder Approval of Merger with Inmagene BiopharmaceuticalsCombined Company to Trade on Nasdaq Under Ticker "IMA" Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA) ("Ikena") today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena's stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals ("Inmagene"). The merger proposal allows for the issuance of shares of Ikena's common stock both to the shareholders of Inmagene and to the investors of the financing concurrent to the merger. Following th
- SECSEC Form 425 filed by Ikena Oncology Inc.425 - Ikena Oncology, Inc. (0001835579) (Subject)
- SECSEC Form 8-K filed by Ikena Oncology Inc.8-K - Ikena Oncology, Inc. (0001835579) (Filer)
IKNA FAQ
7 questionsWhat does Ikena Oncology Inc. do?
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4...Where does IKNA stock trade?
Ikena Oncology Inc. (IKNA) is listed on NASDAQ.What sector and industry is IKNA in?
Ikena Oncology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Ikena Oncology Inc. go public?
Ikena Oncology Inc. (IKNA) completed its IPO in 2021.What are analysts saying about IKNA?
Ikena Oncology Inc. has had 5 recent analyst actions on file. The most recent action was from Wedbush: Neutral with a $200.00 price target on 2024-05-29.What companies are similar to IKNA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IKNA side-by-side with any of them on Quantisnow.How can I track IKNA on Quantisnow?
Quantisnow aggregates Ikena Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IKNA to receive live email and push alerts on every new disclosure.